Loading clinical trials...
Loading clinical trials...
Phase IB Follow-up Study to Assess a Boost Immunization With AFFITOPE AD02 With Regard to Safety/Tolerability, Immunological and Clinical Activity in Alzheimer Patients Who Have Received the Vaccine Within the Clinical Study AFF002
This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who have received the vaccine within the clinical study AFF002.
Age
50 - 85 years
Sex
ALL
Healthy Volunteers
No
Ordination Schmitz
Vienna, Vienna, Austria
Start Date
October 1, 2009
Primary Completion Date
July 1, 2010
Completion Date
July 1, 2010
Last Updated
October 19, 2010
20
ACTUAL participants
AFFITOPE AD02
BIOLOGICAL
Lead Sponsor
Affiris AG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07033494